DPP4 and chronic myelogenous leukemia, BCR-ABL1 positive: To explore the behavior of residual CD26+LCSs over time, we focused our data analysis on three time points (3, 6, and 12 months) of the 71/109 CML patients still in TFR at the last follow-up.